Tdap Vaccination During Pregnancy Likely to Protect Newborns from Pertussis

- Vaccinating pregnant women with Tdap vaccine is safe, induces an immune response in women and is likely to protect their newborn infants against pertussis

- During the third trimester of pregnancy:
  - 33 women: Single dose of Tdap
  - 15 women: Placebo

- Results of NIH-funded clinical trial support maternal vaccination

NIH Scientists Model Immune Variation and Responses to Flu Vaccination

- Approach to model and predict human immune responses to flu vaccination based on state of the immune system
- Frequency of a few immune cell types present before vaccination was sufficient to predict level of the flu-specific antibodies made after vaccination
- Study offers potential framework for predicting a person’s responsiveness to vaccination


www.niaid.nih.gov/topics/immuneSystem/Pages/immuneVariation.aspx
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS)

PI – John Treanor
University of Rochester
Rochester, NY

Co-PI – David Tophman

PI – Richard Webby
St. Jude Children’s Research Hospital
Memphis, TN

Co-PI – Stacey Schultz-Cherry

PI – Adolfo Garcia-Sastre
Mt. Sinai School of Medicine
New York, NY

Co-PI – Andrew Pekosz

PI – Walter Orenstein
Emory University
Atlanta, GA

Co-PI – Dick Compans

Updated 3/2014
Meetings

- Common Barriers in Vaccine Research and Development: June 19 – 20, 2014
  - Workshop sponsored by NIAID and FDA

- NIAID Meeting Report